when you look at something who have usedke heroin in the last month -- that is like an indication of recent heroin users. when you look at that number, there are about 30 300,000 users in the last month. that number is down from 2006. but, if you look at the last year, who has used the drug in the last year? that number is up. it all depends on what your indicators are. we have to be careful. when i say, where we are, i ain't concerned that we tend to think about heroin use -- we tend to go to the frame of the heroin addict. the vast majority of people who use heroin are not addicts. obviously, with the chief is doing is creative, innovative, and i think a great approach. the thing we have to be careful about is just remember, there are people who do not need treatment, they need education about what the real dangers are. shot at youre a question. i think what we have to remember is we are not talking about heroin, we're talking about opiates and painkillers. in my state of vermont, which standards ofe best life in the country -- <> better than chicago? >> better than chicago. i'm no

at -- we usedking as a proxy, real estate access meant in london and new york.oking at appreciation and the value. we are looking at absolute numbers. alix: good stuff. thank you. we'll have bloomberg marketing coming up. scarlet: welcome to bloomberg markets. ♪ ♪ scarlet: from bloomberg world headquarters in new york, olivia: no matter where in the world you look, bonds are gaining. scarlet: what are the benefits of one global company. olivia: the controversy over valley and continues. valiant continues. scarlet: let's go over to the market desk with julie hyman. if you look at equities, we are at session highs. julie: stocks are gaining on the session and gaining steam. bit fromown a little the 10 day average. all three major averages are gaining. biotech stocks in the nasdaq are really ramping up. has been the leader today followed by energy and financials. they are up i more than 1%. we have had all this m&a activity giving fuel to a lot of gains in health care. we are watching pfizer and allergan again. they are making progress on what could be the year's b